Akari Therapeutics (AKTX) AI Stock Analysis

• Market Cap: $31.76M
• Dividend Yield: N/A
• Average Volume (3M): 25.77K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.56
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 32,176,370
• 10 Day Avg. Volume: 24,162
• 30 Day Avg. Volume: 25,768
• PEG Ratio: >-0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: -0.02
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: <0.01
• 1Y Price Target: $6.00
• Price Target Upside: 426.32% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 44 Neutral
• Price Target: ―

Akari Therapeutics' stock score of 44 reflects significant challenges due to its current financial instability and lack of revenue. While the technical analysis indicates a neutral trend, the company's speculative nature due to the absence of traditional valuation metrics underscores the risk. However, the recent positive corporate event with the appointment of a new CEO brings some potential for strategic improvement, slightly offsetting the otherwise high-risk profile.

Positive Factors

Analyst Recommendation

Analyst recommendation is a Buy for Akari Therapeutics stock.

Innovative Technology

Akari Therapeutics is using a novel payload approach in the high-value ADC space.

Pipeline Potential

The key is the departure from toxin-based payloads, along with validated targets could make the Akari pipeline attractive for potential partners.

Negative Factors

Preclinical Stage

PH1-ADCs in preclinical work have demonstrated synergy with checkpoint inhibitors and offer a more favorable toxicity profile, which suggests potential higher therapeutic index.

Akari Therapeutics Business Overview & Revenue Model

Company Description

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

How the Company Makes Money

Akari Therapeutics primarily makes money through the development and commercialization of its proprietary drug candidates. The company generates revenue through partnerships, licensing agreements, and potential sales of its therapeutic products upon receiving regulatory approval. Key revenue streams include milestone payments and royalties from strategic collaborations with larger pharmaceutical companies that have the resources to bring Akari's products to market. Additionally, Akari may receive research and development funding from grants or governmental and non-governmental organizations, supporting its ongoing drug development efforts.

Akari Therapeutics Financial Statement Overview

Summary

Akari Therapeutics is in an early-stage biotechnology phase with no revenue generation and consistent losses, leading to negative cash flow and reliance on external financing. While the company's debt levels are low, the financial instability is evident from the fluctuating equity and persistent cash burn. Sustained financial health will depend on successful product development and commercialization to transition from a loss-making to a revenue-generating entity.

Income Statement

Akari Therapeutics has not generated any revenue over the past years, which is typical for early-stage biotechnology companies but poses a significant risk in terms of financial sustainability. The company reports consistent negative EBIT and net income, indicating ongoing operational losses without any top-line growth. The inability to generate revenue while incurring significant expenses results in a challenging financial position.

Balance Sheet

Despite having no revenue, Akari Therapeutics maintains a relatively low level of debt compared to its equity, demonstrating prudent capital management. However, stockholders' equity has fluctuated, with a substantial deficit in 2023, which indicates financial instability. The equity ratio remains modest, reflecting a need for improved financial performance to stabilize the balance sheet.

Cash Flow

The company has experienced negative operating cash flow consistently, signaling cash burn due to lack of revenue. Although financing cash flow has supported operations through equity raises or debt, the free cash flow remains negative, highlighting the dependency on external financing to sustain operations. This situation underscores the high risk of cash flow shortages if financing becomes constrained.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	―	―	―	―
EBITDA	-21.64M	-16.80M	-23.08M	-17.21M	-20.44M
Net Income	-19.79M	-10.01M	-6.97M	-17.61M	-17.60M
Balance Sheet
Total Assets	50.56M	4.36M	13.83M	11.65M	17.59M
Cash, Cash Equivalents and Short-Term Investments	2.60M	3.85M	13.25M	9.36M	14.06M
Total Debt	3.26M	0.00	0.00	0.00	0.00
Total Liabilities	28.33M	4.58M	12.04M	6.09M	5.22M
Stockholders Equity	22.23M	-229.00K	1.79M	5.55M	12.38M
Cash Flow
Free Cash Flow	-12.55M	-16.43M	-21.50M	-18.85M	-16.95M
Operating Cash Flow	-12.55M	-16.43M	-21.50M	-18.85M	-16.95M
Investing Cash Flow	382.00K	0.00	0.00	0.00	0.00
Financing Cash Flow	10.99M	7.02M	25.29M	14.29M	25.07M

Akari Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AKTX, the sentiment is Negative. The current price of 1.14 is above the 20-day moving average (MA) of 1.14, below the 50-day MA of 1.21, and below the 200-day MA of 1.40, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 47.08 is Neutral, neither overbought nor oversold. The STOCH value of 80.95 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AKTX.

Akari Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LVTX	61 Neutral	$38.41M	―	-73.11%	―	-60.20%	3.85%
Sector *	52 Neutral	kr5.63B	10.07	-63.86%	1.97%	27.19%	26.73%
LTRN	45 Neutral	$45.62M	―	-75.66%	―	―	-31.16%
AKTX	44 Neutral	$31.76M	―	-197.11%	―	―	―
XFOR	44 Neutral	$8.68M	0.67	121.75%	―	―	―
STTK	42 Neutral	$39.26M	―	-71.90%	―	69.65%	27.98%

Akari Therapeutics Corporate Events

Akari Therapeutics Appoints New CEO Abizer Gaslightwala

On March 14, 2025, Akari Therapeutics announced the appointment of Mr. Abizer Gaslightwala as the new President and Chief Executive Officer, effective April 21, 2025. Mr. Gaslightwala, who has a robust background in the pharmaceutical industry with leadership roles at Jazz Pharmaceuticals, Amgen, and Pfizer, will replace Dr. Samir R. Patel, who will step down on April 14, 2025, but remain on the board. This leadership change is expected to bring strategic insights and strengthen Akari’s market position in the biopharmaceutical sector.